Key Points
- CAO Kristen Ambrose sold 1,376 VRTX shares at an average price of $460.43 on Feb. 11 for $633,551.68, trimming her stake by 11.96% to 10,127 shares (about $4.66M).
- Vertex reported Q4 EPS of $5.03 (a slight miss vs. consensus) and revenue of $3.19B (+9.5% YoY), with 2026 revenue guidance of roughly $13.0–13.1B that was broadly in line with expectations.
- Wall Street remains generally bullish with an average price target near $522.68 and multiple upgrades, though high institutional ownership (~90.96%) and recent insider selling are flagged as potential short‑term sentiment risks.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Get Free Report) EVP Ourania Tatsis sold 466 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total transaction of $214,560.38. Following the completion of the sale, the executive vice president owned 51,436 shares of the company's stock, valued at $23,682,677.48. This trade represents a 0.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Ourania Tatsis also recently made the following trade(s):
- On Wednesday, January 7th, Ourania Tatsis sold 4,500 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $474.99, for a total transaction of $2,137,455.00.
Vertex Pharmaceuticals Stock Performance
VRTX opened at $465.02 on Friday. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.68. The firm has a market cap of $117.98 billion, a P/E ratio of 32.79 and a beta of 0.30. The business's fifty day moving average is $459.26 and its 200-day moving average is $427.55.
Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing the consensus estimate of $5.05 by ($0.02). The firm had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.18 billion. Vertex Pharmaceuticals had a net margin of 31.35% and a return on equity of 23.51%. Vertex Pharmaceuticals's quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.98 earnings per share. On average, research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have commented on VRTX shares. UBS Group increased their target price on Vertex Pharmaceuticals from $535.00 to $545.00 and gave the company a "buy" rating in a research report on Monday, January 26th. Leerink Partners lifted their target price on shares of Vertex Pharmaceuticals from $456.00 to $525.00 and gave the stock an "outperform" rating in a research note on Monday, December 29th. Royal Bank Of Canada upgraded shares of Vertex Pharmaceuticals from a "sector perform" rating to an "outperform" rating and upped their price objective for the company from $455.00 to $546.00 in a report on Thursday, January 22nd. Wolfe Research upgraded Vertex Pharmaceuticals from a "peer perform" rating to an "outperform" rating and set a $548.00 price target on the stock in a report on Tuesday, January 6th. Finally, Sanford C. Bernstein raised Vertex Pharmaceuticals from a "market perform" rating to an "outperform" rating in a research note on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $522.68.
Check Out Our Latest Research Report on VRTX
Key Vertex Pharmaceuticals News
Here are the key news stories impacting Vertex Pharmaceuticals this week:
- Positive Sentiment: Revenue and product momentum — Vertex reported Q4 revenue of ~$3.19B (≈+9.5% YoY), which many outlets framed as a beat or in-line with expectations and supports confidence in its CF franchise and near-term cash flow. Read More.
- Positive Sentiment: Analyst backing and long-term targets — Several analysts maintain bullish ratings and above-current price targets (median targets well above the share price), which provides longer-term upside support for the stock. Read More.
- Positive Sentiment: Pipeline diversification — Company commentary and reporting highlighted partnership/expansion efforts (broader autoimmune work) that could reduce concentration risk over time. Read More.
- Neutral Sentiment: 2026 guidance roughly in-line — Management’s revenue guidance (~$13.0–13.1B) came in close to consensus, which limits downside from surprise guidance but doesn’t materially raise expectations. Read More.
- Neutral Sentiment: Full materials available — Investors can review the earnings slide deck and call transcript for details on product and pipeline trends to refine estimates. Read More.
- Negative Sentiment: Small EPS miss and mixed metric comparisons — EPS came in marginally below consensus (~$5.03 vs. ~$5.05–$5.07) and some feeds showed revenue slightly under certain Street models, prompting short-term selling pressure. Read More.
- Negative Sentiment: Insider selling — Multiple senior executives (EVPs and the CAO) disclosed sizeable open-market sales this week, which can amplify negative sentiment even if sales are for diversification or tax planning. Read More.
- Negative Sentiment: After-hours weakness — The combination of the small EPS miss and the insider selling pushed shares lower in after-hours trading, reflecting short-term profit-taking by traders. Read More.
Institutional Investors Weigh In On Vertex Pharmaceuticals
A number of hedge funds have recently modified their holdings of the stock. Chesapeake Asset Management LLC raised its stake in Vertex Pharmaceuticals by 110.0% in the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company's stock valued at $25,000 after acquiring an additional 33 shares during the period. Access Investment Management LLC bought a new stake in shares of Vertex Pharmaceuticals in the second quarter valued at approximately $27,000. Colonial Trust Co SC raised its position in shares of Vertex Pharmaceuticals by 118.8% in the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company's stock valued at $27,000 after purchasing an additional 38 shares during the period. Swiss RE Ltd. purchased a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth $28,000. Finally, Legacy Investment Solutions LLC purchased a new position in shares of Vertex Pharmaceuticals during the 2nd quarter valued at $29,000. Institutional investors own 90.96% of the company's stock.
About Vertex Pharmaceuticals
(
Get Free Report)
Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.
Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
